RET and neoplasm: Sunitinib is an oral, multitargeted TKI targeting VEGFR, Kit, platelet-derived growth factor (PDGFR), FMS-like tyrosine kinase 3 (FLT3) and RET on tumor cells, tumor neovasculature and pericytes [93].